

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

CHANGE IN PARTICULAR OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board of directors (the “Board”) of Dawnrays Pharmaceutical (Holdings) Limited (the “Company”) announces that as “Shell Tower” of Times Square will be renamed as “Tower Two” with effect from 18 May 2011, the principal place of business of the Company in Hong Kong will be changed to Suites 3212-13, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong correspondingly with effect from 18 May 2011.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 16 May 2011

As at the date of this announcement, the Board of the Company comprises of four executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai, Mr. Li Tung Ming, Mr. Gao Yi; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Pan Xue Tian, Mr. Choi Tat Ying Jacky and Mr. Lo Tung Sing Tony.

** For identification purpose only*